|
Match
|
Document |
Document Title |
|
|
US20090304590 |
Therapeutic compositions and methods
The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
|
|
|
US20090306004 |
GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION
A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a...
|
|
|
US20090304720 |
Active Agent-Loaded Nanoparticles Based On Hydrophilic Proteins
Active agent-loaded nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins, and methods for producing the nanoparticles and the use thereof. Functional...
|
|
|
US20090298785 |
Method for Treating Ocular Cancer
It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53...
|
|
|
US20090298786 |
METHODS OF TREATING VIRAL INFECTIONS WITH ANTHRACYCLINE ANTIBIOTICS
A method of treating hepatitis C viral infection or viremia in a patient by administering to the patient an anti-hepatitis C virally effective amount of a compound of Formula 1 or Formula 2. A...
|
|
|
US20090291049 |
Targeted delivery to human diseases and disorders
The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target...
|
|
|
US20090291079 |
TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS
Compounds of formula I
wherein: R 1 is
and R 2 , R 4 , and R 6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3...
|
|
|
US20090274773 |
ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT
A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabi-nofuranosy
l-cytosine, or a metabolite thereof, or a pharmaceutically...
|
|
|
US20090274762 |
REHYDRATABLE PHARMACEUTICAL PRODUCT
A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged...
|
|
|
US20090274753 |
PH-SENSITIVE POLYMERIC MICELLES FOR DRUG DELIVERY
Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug...
|
|
|
US20090263397 |
Combination anti-cancer therapy
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective...
|
|
|
US20090263320 |
Peptide-Based Compounds
The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.
|
|
|
US20090257965 |
ABNORMAL PROTEIN REMOVING COMPOSITION
Provide an effective composition for removing abnormal protein. Also, a composition for removing abnormal protein whose main ingredient is soyasaponin B group, which is used to provide a...
|
|
|
US20090258064 |
COMPOSITIONS OF UCP INHIBITORS, FAS ANTIBODY, A FATTY ACID METABOLISM INHIBITOR AND/OR A GLUCOSE METABOLISM INHIBITOR
Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a...
|
|
|
US20090257951 |
NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
The present invention provides a method of identifying a tumor homing molecule that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more molecules...
|
|
|
US20090238896 |
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MELANOMA
Described herein are compositions and methods for the diagnosis, prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated...
|
|
|
US20090232827 |
Compositions and methods of use of compounds to increase cancer patient survival time
The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses...
|
|
|
US20090232913 |
Composition for the Control of Cholesterol Levels
The present invention relates to a composition used to control cholesterol levels. In particular, the present invention relates to a method for the treatment or prevention of disorders or diseases...
|
|
|
US20090232900 |
NANO-MICELLAR PREPARATION OF ANTHRACYLCLINE ANTITUMOR ANTIBIOTICS ENCAPSULATED BY THE PHOSPHATIDE DERIVATIZED WITH POLYETHYLENE GLYCOL
The present invention provides a nano-micellar preparation of anthracycline antitumor antibiotics for intravenous injection, which comprises a therapeutically effective amount of anthracycline...
|
|
|
US20090227529 |
COMBINATION TREATMENT FOR BLADDER CANCER
Novel methods useful for treating a patient with bladder cancer such as superficial bladder cancer includes administering to the patient a therapeutically effective amount of valrubicin and...
|
|
|
US20090214634 |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER
Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin....
|
|
|
US20090215709 |
Methylation markers for diagnosis and treatment of cancers
Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting...
|
|
|
US20090214435 |
Recombinant vector expressing MDR1 shRNA and thymidine kinase and use thereof
A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and...
|
|
|
US20090214508 |
VEGF-ACTIVATED FAS LIGANDS
The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells...
|
|
|
US20090202541 |
COMBINATION COMPRISING N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL)-4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT
A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which...
|
|
|
US20090196913 |
Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
An immunoliposome composition targeted to the alpha-V-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody...
|
|
|
US20090197821 |
COMPOSITIONS AND METHODS FOR THE DELIVERY OF POORLY WATER SOLUBLE DRUGS AND METHODS OF TREATMENT
The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water-soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5...
|
|
|
US20090192077 |
North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus
A method for the prevention or treatment of Kaposi's sarcoma or Kaposi's sarcoma-associated herpes virus infection by administering an effective amount of a cyclopropanated carbocyclic...
|
|
|
US20090191152 |
INTRALYMPHATIC CHEMOTHERAPY DRUG CARRIERS
A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not...
|
|
|
US20090186839 |
Model for studying the role of genes in chemoresistance
The invention provides novel inhibitors of protein translation initiation and inhibitors of eIF4F activity that can increase chemosensitivity or diminish or reverse chemoresistance in growth...
|
|
|
US20090181090 |
Protein-Based Carrier System for Overcoming Resistance in Tumour Cells
Nanoparticles, the particle matrix of which is based on at least one protein and has at least one active agent embedded therein and methods of producing the nanoparticles with at least one active...
|
|
|
US20090180986 |
TREATING UNWANTED OCULAR CONDITIONS USING AN ASCOMYCIN MACROLACTAM
The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically...
|
|
|
US20090169627 |
PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME
In accordance with one aspect of the invention, injectable particles are provided which comprise (a) a first group of injectable particles comprising first polymeric particles loaded with a first...
|
|
|
US20090162440 |
SODIUM ALGINATE MICROSPHERE VASCULAR EMBOLUS CONTAINING WATER-SOLUBLE DRUG AND PREPARATION AND APPLICATION THEREOF
The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into...
|
|
|
US20090162288 |
Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject...
|
|
|
US20090156469 |
METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF IN TREATING WALDENSTROM'S MACROGLOBULINEMIA
Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.
|
|
|
US20090149399 |
HETEROCYCLIC KINASE INHIBITORS
This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin
-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and...
|
|
|
US20090136496 |
CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND TREATMENT
Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence...
|
|
|
US20090130228 |
PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS
This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer...
|
|
|
US20090130097 |
Quinazolinone Compounds and Methods of Use Thereof
The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the...
|
|
|
US20090130229 |
Antitumor uses of compound
The use of an arylidene 2-indolinone derivative for treating tumors involving Met, PDGF-R, FGF-RI, FGF-R3 or Kit tyrosine kinases, or a Ret oncoprotein which includes a MEN2-associated mutation is...
|
|
|
US20090123567 |
BISBENZISOSELENAZOLONYL DERIVATIVES HAVING ANTINEOPLASTIC, ANTI-INFLAMMATORY AND ANTITHROMBOTIC ACTIVITIES AS WELL AS THEIR USE
The present invention relates to new bisbenzisoselenazolonyl derivatives of the following general formula (I), wherein R is C 4-5 -alkylene, and their pharmaceutically acceptable salts. The...
|
|
|
US20090123420 |
Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase
The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor.
|
|
|
US20090117176 |
Anticancer Treatments
A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin (“PLD”), in combination...
|
|
|
US20090118164 |
METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH
Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R T ), having an affinity for bone; a Bone Active Portion (R A ) for interacting with and affecting...
|
|
|
US20090117203 |
KIT FOR CANCER TREATMENT AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
To provide a kit for cancer treatment and a pharmaceutical composition for cancer treatment that can inhibit the growth of tumors and cancers in mammals more than ever. The kit for cancer...
|
|
|
US20090118205 |
Antisense Oligonucleotides Directed to Ribonucleotide Reductase R2 and uses Thereof in the Treatment of Cancer
The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more...
|
|
|
US20090110644 |
Polymer nanoparticles coated by magnetic metal oxide and uses thereof
The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the...
|
|
|
US20090110678 |
RECEPTOR ANTAGONISTS FOR TREATMENT OF METASTATIC BONE CANCER
The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides...
|
|
|
US20090105128 |
CANNABINOID RECEPTOR TARGETED AGENT
Compounds of the following formula:
wherein X is H or substituted with
with at least one X being substituted; and halo is fluorine, chlorine, bromine, iodine; and stereoisomers and conjugable...
|